Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.
Saved in:
| Title: | Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD. |
|---|---|
| Authors: | Jaramillo, Sonia1 (AUTHOR) Sonia.jaramillosegura@med.uni-heidelberg.de, Le Cornet, Lucian2 (AUTHOR), Kratzmann, Markus2 (AUTHOR), Krisam, Johannes3 (AUTHOR), Görner, Martin4 (AUTHOR), Hänel, Mathias5 (AUTHOR), Röllig, Christoph6 (AUTHOR), Wass, Maxi7 (AUTHOR), Scholl, Sebastian8 (AUTHOR), Ringhoffer, Mark9 (AUTHOR), Reichart, Alexander10 (AUTHOR), Steffen, Björn11 (AUTHOR), Kayser, Sabine12 (AUTHOR), Mikesch, Jan-Henrik13 (AUTHOR), Schaefer-Eckart, Kerstin14 (AUTHOR), Schubert, Jörg15 (AUTHOR), Geer, Thomas16 (AUTHOR), Martin, Sonja17 (AUTHOR), Kieser, Meinhard17 (AUTHOR), Sauer, Tim1 (AUTHOR) |
| Source: | Trials. 9/15/2023, Vol. 24 Issue 1, p1-15. 15p. 3 Charts, 1 Graph. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
